Cytosorbents Corporation
CTSO
$1.13
$0.032.73%
| Weiss Ratings | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.97 | |||
| Price History | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 11.88% | |||
| 30-Day Total Return | 13.00% | |||
| 60-Day Total Return | 39.49% | |||
| 90-Day Total Return | 29.81% | |||
| Year to Date Total Return | 22.83% | |||
| 1-Year Total Return | 16.97% | |||
| 2-Year Total Return | -64.91% | |||
| 3-Year Total Return | -66.07% | |||
| 5-Year Total Return | -72.84% | |||
| 52-Week High % Change | -29.81% | |||
| 52-Week Low % Change | 61.43% | |||
| Price | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.61 | |||
| 52-Week Low Price | $0.70 | |||
| 52-Week Low Price (Date) | Jul 01, 2024 | |||
| 52-Week High Price (Date) | Feb 14, 2025 | |||
| Valuation | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 61.79M | |||
| Enterprise Value | 82.91M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.36 | |||
| Earnings Per Share Growth | -32.05% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.63 | |||
| Price/Book (Q) | 4.74 | |||
| Enterprise Value/Revenue (TTM) | 2.20 | |||
| Price | $1.13 | |||
| Enterprise Value/EBITDA (TTM) | -4.19 | |||
| Enterprise Value/EBIT | -3.88 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 54.45M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 732 329 8885 | |||
| Address | 305 College Road East Princeton, NJ 08540 | |||
| Website | www.cytosorbents.com | |||
| Country | United States | |||
| Year Founded | 1997 | |||
| Profitability | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -56.63% | |||
| Profit Margin | -49.47% | |||
| Management Effectiveness | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -28.01% | |||
| Return on Equity | -- | |||
| Income Statement | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 37.74M | |||
| Total Revenue (TTM) | 37.74M | |||
| Revenue Per Share | $0.69 | |||
| Gross Profit (TTM) | 23.67M | |||
| EBITDA (TTM) | -19.80M | |||
| EBIT (TTM) | -21.37M | |||
| Net Income (TTM) | -18.67M | |||
| Net Income Avl. to Common (TTM) | -18.67M | |||
| Total Revenue Growth (Q YOY) | 6.58% | |||
| Earnings Growth (Q YOY) | 74.61% | |||
| EPS Diluted (TTM) | -0.36 | |||
| EPS Diluted Growth (Q YOY) | 79.30% | |||
| Balance Sheet | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.69M | |||
| Cash Per Share (Q) | $0.10 | |||
| Total Current Assets (Q) | 16.60M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 13.00M | |||
| Current Ratio (Q) | 1.969 | |||
| Book Value Per Share (Q) | $0.24 | |||
| Total Assets (Q) | 47.80M | |||
| Total Current Liabilities (Q) | 8.43M | |||
| Total Debt (Q) | 26.81M | |||
| Total Liabilities (Q) | 34.80M | |||
| Total Common Equity (Q) | 13.00M | |||
| Cash Flow | CTSO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -681.20K | |||
| Cash from Financing (TTM) | 21.37M | |||
| Net Change in Cash (TTM) | 2.12M | |||
| Levered Free Cash Flow (TTM) | -11.70M | |||
| Cash from Operations (TTM) | -18.49M | |||
